Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies

Abstract

Our study provides a strong rationale for considering daptomycin dosages of ≥ 8 mg/kg/day in several clinical scenarios for oncohaematological patients. In some of these scenarios therapeutic drug monitoring could be a useful adjunct for optimized care.